In Celexir’s specialized toolkit, AC-KPV-NH2 is positioned for cases where calming skin/gut inflammation and restoring epithelial balance are clinical priorities. Providers use it as an adjunct in dermatologic recovery plans and gut-barrier protocols to reduce flare activity while broader drivers—sleep, stress, diet, microbiome—are addressed.
Mechanistically, KPV is a bioactive α-MSH–derived tripeptide that binds melanocortin receptors (notably MC1R/MC3R) to repress NF-κB signaling and down-shift pro-inflammatory cytokines such as TNF-α and IL-6; these same pathways promote epithelial healing in barrier tissues (skin and intestinal mucosa). This α-MSH/KPV axis is well described across basic and translational literature as a potent anti-inflammatory, cytoprotective signal.
Evidence signals: in preclinical and translational models, KPV attenuates colitis, improves tight-junction integrity, and shows anti-inflammatory effects in cutaneous and mucosal tissues—supporting its use where barrier restoration is a goal. Human data remain limited; position AC-KPV-NH2 as an investigational adjunct with objective tracking (symptom scores, flare frequency, dermatologic indices), and integrate with standard care.
Celexir delivery & specs: typically 250–500 mcg/day per protocol in a ready-to-use injectable pen; >98% purity, 2–8 °C storage, and full CoA/MSDS to keep workflows consistent and compliant from warehouse to administration.